Bristol-Myers Squibb Co. has terminated the three Phase III studies of its in-house IDO inhibitor BMS-986205 in melanoma, head and neck, and lung cancer – an asset acquired through a high-priced acquisition of Flexus Biosciences Inc. in 2015.
Indoleamine 2,3-dioxygenase (IDO1) is an enzyme that plays an important part in immune response. (Also see "Scrip's Rough Guide To IDO" - Scrip, 18 May, 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?